文献速递浆细胞疾病血栓与止血

多发性骨髓瘤中的血栓形成:按诱导方案的风险估计及其与总生存期的关联

Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
PubMed 文献 · Am J Hematol · 2023-01-01

在梅奥诊所罗切斯特院区接受来那度胺为基础的三药或四药诱导治疗的672例新诊断多发性骨髓瘤患者中,血栓栓塞发生率为12.4%,卡非佐米联合来那度胺及地塞米松方案风险最高(21.1%),血栓栓塞与总生存期缩短相关(66 vs 133个月,P<.01)。

要点

  • 来那度胺为基础诱导治疗的新诊断骨髓瘤患者中,血栓栓塞发生率为12.4%。
  • 卡非佐米联合来那度胺及地塞米松方案血栓栓塞风险最高(21.1%),与其他方案差异有统计学意义(OR=2.6,P<.01)。
  • 发生血栓栓塞的患者总生存期显著缩短(66 vs 133个月,P<.01),多因素分析中关联仍存在(HR=2.61,95%CI=1.74-3.9)。

核心结论

  • 血栓栓塞是多发性骨髓瘤管理的重要方面,在新药治疗时代有效管理尤为重要。

研究设计与样本

  • 在梅奥诊所罗切斯特院区开展的研究,纳入672例接受来那度胺为基础三药或四药诱导治疗的新诊断多发性骨髓瘤患者。
  • 评估诊断后第一年内血栓栓塞发生率、其与诱导方案类型的关系及对总生存期的影响。

主要发现

  • 83例(12.4%)诊断为血栓栓塞,其中深静脉血栓56例(8.3%),肺栓塞伴或不伴深静脉血栓23例(3.4%),卒中4例(0.6%)。
  • 卡非佐米联合来那度胺及地塞米松方案血栓栓塞风险最高(21.1%,18/85),其次为四药方案(11.1%,5/45)、硼替佐米联合来那度胺及地塞米松(9.6%,51/531),其他来那度胺为基础方案为0/11(0%)。
  • 卡非佐米联合来那度胺及地塞米松方案与其他方案的血栓栓塞风险差异有统计学意义(OR=2.6,P<.01)。
  • 9例患者在暴露于任何治疗前发生血栓栓塞。
  • 发生血栓栓塞的患者总生存期显著较低(66 vs 133个月,P<.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenalidomide-containing (R) triplet and quadruplet regimens are the standard of care for multiple myeloma (MM) and have been shown to increase the risk of thrombosis. The association between thromboembolism (TE) and survival in the novel multidrug era is not yet delineated. In this study, we evaluated the incidence of TE during the first year of MM diagnosis, its association with the type of induction regimen, and its impact on overall survival. We studied 672 newly diagnosed MM (NDMM) patients who received a triplet or quadruplet lenalidomide-based induction at the Mayo Clinic, Rochester. TE was diagnosed in 83 patients (12.4%). Of these, 56 (8.3%) had a deep venous thrombosis (DVT), 23 (3.4%) had a pulmonary embolism (PE) with or without the DVT, and 4 (0.6%) patients had a stroke. Carfilzomib-Rd (KRd) had the highest risk of TE (21.1%, 18/85), followed by quadruplets (11.1%, 5/45), bortezomib-Rd (9.6%, 51/531), and 0/11 (0%), treated with other lenalidomide-containing regimens. The difference in TE risk between KRd and the other regimens was statistically significant (OR = 2.6, p < .01). Nine patients developed a TE before being exposed to any treatment. Survival was significantly lower among patients that developed a TE (66 vs. 133 months, p < .01). The association of TE with reduced survival demonstrated in univariate analysis (HR = 2.2, 95% CI = 1.6-3.3) was maintained in the multivariable analysis adjusted for high-risk interphase fluorescence in situ hybridization (FISH), sex, age, receipt of an upfront transplant, the response at induction, and the International Staging System (ISS) (HR = 2.61, CI = 1.74-3.9). We conclude that TE is an important aspect of MM management, and effective management is especially relevant in the novel treatment era.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Charalampous C, Goel U, Kapoor P, et al. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. Am J Hematol. 2023. PMID: 36588396. doi:10.1002/ajh.26806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。